Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies
Status:
Terminated
Trial end date:
2020-06-22
Target enrollment:
Participant gender:
Summary
This is an open-label, dose escalation Phase I study to evaluate the tolerability and
efficacy of single agent of Nivolumab as maintenance treatment to prevent relapse in patients
with hematologic malignancies after allogeneic stem cell transplantation. Approximately 29
patients will be enrolled, where about 6-12 patients will be included on the dose escalation
phase and 20 patients will be on the expansion cohort at maximal tolerated dose.